Nano-liposome capable of efficiently resisting bacteria and inhibiting activity of beta-galactosidase as well as preparation method and application of nano-liposome

Nanoliposomes were prepared by combining astragalus, curcumin, baicalin and quercetin with surfactants, which solved the problem of poor effect of existing antibacterial substances and achieved multiple targets and multiple mechanisms Antibacterial and anti-aging effects, with the potential to replace antibiotics.

CN118903153APending Publication Date: 2024-11-08WANG SHUHE BIOMEDICINE (WUHAN) CO LTD
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202410958504.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-17
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The effect of existing antibacterial substances is not ideal, causing bacteria to develop drug resistance and threatening human health.

Method used

Develop a nanoliposome that is highly effective in antibacterial and inhibits β-galactosidase activity. By combining cycloalisation alcohol, curcumin, baicalin and quercetin with surfactant, lecithin, etc., high-pressure homogeneous circulation is adopted Under treatment and shearing conditions, liquid lipids were added dropwise to prepare stable nanoliposomes.

Benefits of technology

It has achieved a multi-angle, multi-target, and multi-mechanism to significantly improve the health of the body, with broad-spectrum antibacterial properties, reduces the spread of pathogens, delays aging, improves inflammation and oxidative damage, and is safe and low-toxic due to plant origins. The potential of alternative antibiotics.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903153A_ABST
    Figure CN118903153A_ABST
Patent Text Reader

Abstract

The invention discloses a nano-liposome capable of efficiently resisting bacteria and inhibiting beta-galactosidase activity as well as a preparation method and application of the nano-liposome, belongs to the technical field of nano-liposomes, and solves the problem of non-ideal action effect of an antibacterial substance in the prior art. Every 100 parts by weight of the nano-liposome comprises the following components in parts by weight: 2-4 parts of cycloastragenol, 1-3 parts of curcumin, 1-3 parts of baicalein, 1-3 parts of quercetin, 10-20 parts of a surfactant, 5-10 parts of lecithin, 20-30 parts of a cosurfactant, 5-10 parts of liquid lipid, 1-5 parts of an enhancer, 5-10 parts of absolute ethyl alcohol and the balance of water. According to the composition provided by the invention, all the components have a synergistic effect, so that excellent antibacterial and anti-aging effects are achieved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of nanoliposomes, and more specifically to a nanoliposome capable of highly effective antibacterial and beta-galactosidase activity inhibition, a preparation method and application thereof. Background Art

[0002] Cycloastragenol, a triterpenoid saponin compound, is a secondary metabolite extracted from Astragalus. Its structure is a cycloartane type in tetracyclic triterpenes. Cycloastragenol can inhibit inflammatory aging by inhibiting the activation of inflammasome NLRP3; it can reduce mitochondrial-dependent cell death by inhibiting endoplasmic reticulum stress. Cycloastragenol is the only reported telomerase activator among natural products.

[0003] Curcumin is a β-diketone polyphenol compound extracted from the ginger plant turmeric. It is also one of the first nine natural pigments that can be used as food additives in my country. The structure of curcumin contains multiple active groups such as phenolic hydroxyl, carbonyl and double bonds. It has active chemical properties and a wide range of physiological activities. It has good anti-inflammatory, antibacterial, antioxidant and anti-tumor properties. Curcumin also has a broad-spectrum antibacterial activity and has a strong inhibitory effect on a variety of Gram-positive and Gram-negative bacteria. It can kill a variety of pathogenic bacteria such as Streptococcus mutans, Escherichia coli, Staphylococcus aureus, Staphylococcus epidermidis and Enterococcus. In addition, curcumin can enhance the fusion of intracellular lysosomes, thereby reducing the spread of pathogens between cells. However, due to its own unstable nature, its development and application in the field of functional foods are subject to certain restrictions.

[0004] Baicalein is one of the main flavonoid components of Scutellaria baicalensis, a plant of the Labiatae family. Studies have found that baicalein has a variety of pharmacological effects, including liver protection, anti-inflammatory, antiviral, and cardiovascular protection. Baicalein mainly improves the body's immune capacity by regulating the activity of immune cells and the expression of cytokines, including the activation of macrophages and lymphocytes, the production of interleukins (ILs), interferons (IFNs), and tumor necrosis factors (TNFs), and the regulation of NF-κB and MAPKs signaling pathways. Baicalein can also regulate L-type Ca 2+ Ca channels 2+ It can maintain homeostasis, reduce oxidative stress, inflammation and cell apoptosis, and relieve pathological conditions such as myocardial infarction. In addition, baicalin has a broad-spectrum antibacterial effect, which can not only inhibit Gram-positive bacteria such as Staphylococcus aureus and methicillin-resistant Staphylococcus aureus, but also effectively inhibit Gram-negative bacteria such as Pseudomonas aeruginosa, Acinetobacter baumannii (CRAB), Helicobacter pylori, and fungi such as Candida albicans.

[0005] Quercetin (Que), a flavonoid compound, is widely found in fruits and vegetables. As a natural secondary metabolite of plants, quercetin has a strong ability to neutralize free radicals in cells and reduce Cu 2+ Its catechol structure can also react with Fe 2+ , Cu 2+ Quercetin can chelate common metal ions such as succinate and chloramphenicol to form stable multicyclic complexes, thereby exerting an antioxidant effect. Quercetin can increase the concentration of superoxide dismutase (SOD), glutathione peroxidase (GSH-Px) and catalase (CAT) in animals, reduce serum malondialdehyde (MDA) content, and improve animal health through antioxidant, antibacterial, and immune regulation. In addition, quercetin has a broad-spectrum antibacterial effect, and its antibacterial effect on Gram-negative bacteria is stronger than that on Gram-positive bacteria. It can exert a more obvious antibacterial effect on bacteria such as Staphylococcus aureus, Escherichia coli, and Enterococcus, and also has a certain antibacterial effect on fungi and molds.

[0006] At present, the abuse of antibiotics has caused many bacteria to develop drug resistance, which seriously threatens human health. It has become an urgent task to develop antibacterial drugs with high efficiency, low toxicity and strong drug resistance. Summary of the invention

[0007] The present invention provides a nanoliposome with high efficiency in antibacterial and beta-galactosidase activity inhibition, a preparation method and application thereof, and is used to solve the problem that the antibacterial effect in the prior art is not ideal.

[0008] In the first aspect, the present invention provides a nanoliposome with high antibacterial and β-galactosidase activity inhibition, comprising per 100 parts by weight: 2-4 parts of cycloastragenol, 1-3 parts of curcumin, 1-3 parts of baicalein, 1-3 parts of quercetin, 10-20 parts of surfactant, 5-10 parts of lecithin, 20-30 parts of cosurfactant, 5-10 parts of liquid lipid, 1-5 parts of enhancer, 5-10 parts of anhydrous ethanol, and the balance is water. Exemplarily, in the nanoliposome, per 100 parts by weight: 4 parts of cycloastragenol, 2 parts of curcumin, 2 parts of baicalein, 2 parts of quercetin, 20 parts of surfactant, 8 parts of lecithin, 30 parts of cosurfactant, 8 parts of liquid lipid, 3 parts of enhancer, 8 parts of anhydrous ethanol, and the balance is water.

[0009] As a possible implementation, the surfactant is one or a combination of Tween 85, Tween 80, Tween 20, Span 80, Span 60, polyglycerol monooleate, polyglycerol-10 oleate, polyoxyethylene castor oil, and propylene glycol fatty acid ester; and / or the lecithin is one or a combination of hydrogenated lecithin, soybean lecithin, egg yolk lecithin, and sunflower lecithin; and / or the co-surfactant is diethylene glycol monoethyl ether, 1,3-propylene glycol, 1,2-butylene glycol, 1,2-pentanediol. , 1,2-hexanediol, dipropylene glycol, octyldodecanol, maltitol and lactitol, or a combination thereof; and / or the liquid lipid is castor oil, corn oil, soybean oil, olive oil, rapeseed oil, linoleic acid, camellia oil, medium-chain triglycerides, caprylic and capric acid mono- and diglycerides, sucrose fatty acid esters, isopropyl myristate, or a combination thereof; and / or the enhancer is polypropylene oxide block copolymer, chitosan, polyethylene glycol, pectin, polyethylene oxide, polylactic acid-glycolic acid copolymer, or a combination thereof.

[0010] In a second aspect, the present invention provides a method for preparing the nanoliposomes described in any possible implementation of the first aspect, comprising the following steps: uniformly mixing the cycloastragenol, the curcumin, the baicalein, the quercetin and the surfactant to obtain a mixture A; uniformly mixing the liquid lipid, the lecithin and the anhydrous ethanol to obtain a mixture B; uniformly mixing the co-surfactant, the enhancer and the water to obtain a mixture C; adding the mixture B to the mixture A at 40 to 50° C. to obtain a mixture D; adding the mixture C dropwise to the mixture D under shear conditions, performing a high-pressure homogenization circulation treatment and cooling to room temperature to obtain the nanoliposomes.

[0011] As a possible implementation method, the preparation conditions of the mixture A are: ultrasonic treatment at 40-60°C for 30-50min; and / or, the preparation conditions of the mixture B are: stirring at a speed of 300-500rpm for 15-30min at 50-80°C; and / or, the preparation conditions of the mixture C are: stirring at a speed of 100-300rpm for 20-30min at 40-60°C; and / or, the preparation conditions of the mixture D are: stirring at a speed of 200-400rpm for 10-20min; and / or, the shearing conditions are: a speed of 6000-8000rpm, a temperature of 40-60°C, and a duration of 5-15min; and / or, the number of cycles of the high-pressure homogenization cycle treatment is 4 to 6 times.

[0012] In a third aspect, the present invention provides a use of the nanoliposome described in any possible implementation of the first aspect or the nanoliposome prepared by the preparation method described in any possible implementation of the second aspect in the preparation of an antibacterial agent.

[0013] As a possible implementation manner, the nanoliposome is used to inhibit Gram-positive bacteria and / or Gram-negative bacteria.

[0014] As a possible implementation manner, the nanoliposome is used to inhibit Staphylococcus aureus and / or Escherichia coli.

[0015] In a fourth aspect, the present invention provides a use of the nanoliposome described in any possible implementation of the first aspect or the nanoliposome prepared by the preparation method described in any possible implementation of the second aspect in the preparation of an anti-aging agent.

[0016] As a possible implementation, the nanoliposome is used to improve cell inflammation; and / or, the nanoliposome is used to improve cell oxidative damage; and / or, the nanoliposome is used to promote the proliferation of human skin fibroblasts; and / or, the nanoliposome is used to inhibit the action of β-galactosidase.

[0017] A nanoliposome provided by the present invention, wherein the active ingredient cycloastragenol activates telomerase through the mitogen-activated protein kinase (MAPK) pathway, prolongs the length of cell telomeres, enhances tissue repair and regeneration processes, and delays aging; curcumin can enhance the endogenous antioxidant capacity of the body, significantly inhibit lipid peroxidation, protect lipids and hemoglobin from being damaged by free radicals, and reduce the inflammatory response of the body by inhibiting the expression of cyclooxygenase, lipoxygenase and a variety of inflammatory mediators or reducing their activity, and can improve insulin resistance and reduce blood sugar levels; baicalein has the ability to significantly enhance the body's immunity, helping to resist the harm of external bacteria, fungi and viruses; quercetin has a preventive and therapeutic effect on a variety of diseases caused by oxidative stress due to its antioxidant properties, such as cardiovascular disease, cancer and neurodegenerative diseases. The present invention uses cycloastragenol, curcumin, baicalein and quercetin in combination, and the strategy of using a variety of active substances in combination can utilize the complementarity of the mechanism of action between active substances, improve the overall efficacy of the product, and reduce the side effects or toxicity of a single ingredient. This specific combination can significantly improve the health of the body from multiple angles, multiple targets and multiple mechanisms. Its active ingredients all come from plants, with a wide range of raw material sources, no cytotoxicity and few side effects. It has extremely high application prospects in the fields of medicine and health care products.

[0018] The present invention provides a nanoliposome, curcumin, and representative flavonoid compounds quercetin and baicalein, as broad-spectrum antibacterial substances, are effective botanical fungicides that can be used to prevent and treat various bacterial and fungal infectious diseases. After baicalein is combined with quercetin, the expression of mycelium-specific genes (such as ALS, HYR1 and CPH1) can be downregulated to a greater extent compared with the baicalein single-use group and the quercetin single-use group, and there is a synergistic effect in antibacterial and bactericidal aspects. Baicalein combined with quercetin and curcumin can inhibit the escape of intracellular pathogens, reduce the spread of pathogens, and further enhance the antibacterial effect of the composition in the body. In addition, since the nanoliposome provided by the present invention can act on different targets of pathogenic microorganisms, it makes it difficult for pathogenic microorganisms to develop resistance to a single mechanism of action, and has a lower risk of resistance development than antibiotics. The properties of plant origin also make it extremely safe and environmentally friendly. The combination of cycloastragenol, curcumin, baicalein and quercetin can not only delay the aging process, improve the body's oxidative damage, relieve and treat various inflammations, enhance the body's immunity, and promote health, but also has broad-spectrum antibacterial properties, can reduce the occurrence of bacterial infections in animals, and has the potential to replace antibiotics. The nanoliposome provided in this application can be added as an additional ingredient to various medicines, foods, and health products.

[0019] The present invention provides a nanoliposome, wherein the active ingredient cycloastragenol has poor water solubility and low oral bioavailability, and due to the presence of cyclopropane groups, has poor acid resistance and is easily converted into astragenol under acidic conditions; the stability of curcumin is easily affected by various environmental factors, such as easy decomposition under acidic and alkaline conditions, and the hydrophobic groups in the structure cause it to have low water solubility, limiting the effect of the drug; the structural characteristics of baicalein include multiple phenolic hydroxyl groups, which are the main obstacles to its water solubility; the low solubility of quercetin in water is caused by the intermolecular conjugated keto-enol structure and the intramolecular hydrogen bonds formed by hydroxyl groups. The closed nano-scale vesicles prepared by liposome technology have good water solubility and stability. Therefore, in a preparation method of a nano-liposome provided by the present invention, cycloastragenol, curcumin, baicalein, and quercetin are encapsulated and integrated into the same nano-carrier by liposome encapsulation technology, which can promote the penetration of active substances, improve stability, and transport them to targeted cells to exert therapeutic effects, improve the efficiency of action, and prolong the duration of action, thereby realizing the co-transportation of drug components with multiple mechanisms and multiple targets, achieving synergistic synergy, and improving the effect. Physically modifying and encapsulating the four active ingredients by nano-liposomes can improve the stability of drug components in the intestine and improve the therapeutic stability of the drug. At the same time, on the basis of maintaining the original performance of the drug, the shortcomings of poor solubility, poor stability, and low bioavailability of the ingredients are solved. Nano-liposomes can enhance the contact between drug molecules and cells, improve targeting, and have a good sustained-release effect due to the characteristics of small size and surface effect, and can ensure the concentration of active substances within a certain time range. Compared with other encapsulation technologies, nanolipid carrier technology has high loading capacity, high physical stability and good biocompatibility, which overcomes the poor stability of curcumin and cycloastragenol and has strong application potential. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0021] Figure 1 This is a statistical graph of the cell anti-inflammatory experiment results provided in an embodiment of the present invention, wherein, compared with the LPS group, *P<0.05, **P<0.01, ***P<0.005, ****P<0.0001.

[0022] Figure 2This is a statistical graph of the results of the anti-oxidative damage experiment provided in an embodiment of the present invention, wherein, compared with the H2O2 group, *P<0.05, **P<0.01, ***P<0.005, ****P<0.0001.

[0023] Figure 3 This is a statistical graph of the antibacterial test results provided by an embodiment of the present invention, wherein, compared with the negative group, *P<0.05, **P<0.01, ***P<0.005, ****P<0.0001.

[0024] Figure 4 This is a microscopic observation diagram of the cell proliferation efficacy experiment provided in an embodiment of the present invention.

[0025] Figure 5 This is a statistical graph of the results of the cell proliferation efficacy experiment provided in an embodiment of the present invention, wherein, compared with the blank group, *P<0.05, **P<0.01, ***P<0.005, ****P<0.0001.

[0026] Figure 6 This is a schematic diagram of the anti-aging experimental results provided by an embodiment of the present invention. DETAILED DESCRIPTION

[0027] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0028] In order to solve the problem that the antibacterial effect in the prior art is not ideal, the embodiment of the present invention provides a nanoliposome and a preparation method and application thereof.

[0029] The present invention provides a nanoliposome, whose specific combination of active ingredients can significantly improve the health of the body from multiple angles, multiple targets and multiple mechanisms. Moreover, the active ingredients are all derived from plants, with a wide source of raw materials, no cytotoxicity and little side effects, and it has extremely high application prospects in the fields of medicine and health care products.

[0030] Furthermore, the present invention provides a stability test experiment of nanoliposomes, which verifies that the preparation method provided by the present invention is of great significance in promoting the stability of the product.

[0031] Furthermore, the present invention provides a cell anti-inflammatory experiment, an antioxidant damage experiment, an antibacterial experiment, a cell proliferation efficacy experiment and an anti-aging experiment of a nanoliposome, which verifies that the nanoliposome provided by the present invention has excellent effects on improving cell inflammation, antioxidant damage, antibacterial and antibacterial ability, promoting cell proliferation and anti-aging effect; and proves that the active components of a nanoliposome provided by the present invention have a synergistic effect in exerting the above-mentioned effects.

[0032] The technical solution of the present invention will be further described below in conjunction with specific embodiments.

[0033] Example 1

[0034] This example provides a preparation experiment of nanoliposomes.

[0035] 4 parts of cycloastragenol, 2 parts of curcumin, 2 parts of baicalein, 2 parts of quercetin and 20 parts of Tween 85 were mixed by mass ratio, and ultrasonically treated at 50°C for 50 minutes to obtain mixture Ⅰ-A;

[0036] 10 parts of castor oil, 8 parts of hydrogenated lecithin and 8 parts of anhydrous ethanol were mixed, and the mixture was stirred at 70°C and 450 rpm for 25 minutes to obtain a mixture I-B;

[0037] 30 parts of diethylene glycol monoethyl ether, 3 parts of poloxamer 407 and water were mixed, and the mixture was stirred at 250 rpm for 30 min at 50°C to obtain a mixture I-C.

[0038] The mixture I-B was cooled to 50°C and then slowly added into the mixture I-A, and stirred at 350 rpm for 20 min to obtain a mixture I-D;

[0039] Mixture Ⅰ-C was added dropwise into mixture Ⅰ-D under shear conditions, with a shear rate of 8000 rpm, a temperature of 50°C and a time of 10 min; then transferred to a high-pressure homogenizer and subjected to high-pressure homogenization cycle treatment at a pressure of 100 MPa, cycled 5 times, and cooled to room temperature to obtain liposome Ⅰ.

[0040] Example 2

[0041] This example provides a preparation experiment of nanoliposomes.

[0042] 4 parts of cycloastragenol, 2 parts of curcumin, 2 parts of baicalein, 2 parts of quercetin and 15 parts of Span 80 were mixed by mass ratio, and ultrasonically treated at 40°C for 30 minutes to obtain a mixture II-A;

[0043] 8 parts of caprylic acid mono- and di-glycerides, 10 parts of soybean lecithin and 10 parts of anhydrous ethanol were mixed, and the mixture was stirred at 80°C and 500 rpm for 15 minutes to obtain a mixture II-B;

[0044] 30 parts of 1,3-propylene glycol, 5 parts of chitosan and water were mixed, and magnetic stirring was performed at 250 rpm for 30 min at 50°C to obtain a mixture II-C;

[0045] The mixture II-B was cooled to 40°C and then slowly added into the mixture II-A, and stirred at 400 rpm for 10 min to obtain a mixture II-D;

[0046] Mixture II-C was added dropwise into mixture II-D under shear conditions at a shear rate of 6000 rpm, a temperature of 60°C and a time of 15 min; then the mixture was transferred to a high-pressure homogenizer and subjected to high-pressure homogenization cycle treatment at a pressure of 80 MPa for 6 cycles, and then cooled to room temperature to obtain liposome II.

[0047] Example 3

[0048] This example provides a preparation experiment of nanoliposomes.

[0049] 2 parts of cycloastragenol, 3 parts of curcumin, 1 part of baicalein, 3 parts of quercetin and 10 parts of polyglycerol-10 oleate were mixed by mass ratio, and ultrasonically treated at 60°C for 45 minutes to obtain mixture III-A;

[0050] 5 parts of sucrose fatty acid ester, 10 parts of egg yolk lecithin and 5 parts of anhydrous ethanol were mixed, and magnetically stirred at 300 rpm for 30 min at 50°C to obtain mixture III-B;

[0051] 20 parts of 1,2-hexanediol, 1 part of pectin and water were mixed, and the mixture was stirred at 100 rpm for 25 minutes at 40°C to obtain mixture III-C;

[0052] The mixture III-B was cooled to 40°C and then slowly added into the mixture III-A, and stirred at 200 rpm for 15 min to obtain a mixture III-D;

[0053] The mixture III-C was added dropwise into the mixture III-D under shear conditions, with a shear rate of 7000 rpm, a temperature of 40°C and a time of 5 min; then it was transferred to a high-pressure homogenizer and subjected to a high-pressure homogenization cycle treatment at a pressure of 120 MPa, cycled 4 times, and cooled to room temperature to obtain liposome III.

[0054] Comparative Example 1

[0055] This example provides a preparation experiment of nanoliposomes.

[0056] 2 parts of curcumin, 2 parts of baicalein, 2 parts of quercetin and 20 parts of Tween 85 were mixed by mass ratio, and ultrasonically treated for 50 min at 50°C to obtain a mixture IV-A;

[0057] 10 parts of castor oil, 8 parts of hydrogenated lecithin and 8 parts of anhydrous ethanol were mixed, and the mixture was stirred at 70°C and 450 rpm for 25 minutes to obtain a mixture IV-B.

[0058] 30 parts of diethylene glycol monoethyl ether, 3 parts of poloxamer 407 and water were mixed, and the mixture was stirred at 250 rpm for 30 min at 50°C to obtain a mixture IV-C.

[0059] The mixture IV-B was cooled to 50°C and then slowly added to the mixture IV-A, and stirred at 350 rpm for 20 min to obtain a mixture IV-D;

[0060] The mixture IV-C was added dropwise into the mixture IV-D under shear conditions, with a shear rate of 8000 rpm, a temperature of 50°C and a time of 10 min; then the mixture was transferred to a high-pressure homogenizer and subjected to a high-pressure homogenization cycle treatment at a pressure of 100 MPa, cycled 5 times, and cooled to room temperature to obtain liposome IV.

[0061] Comparative Example 2

[0062] This example provides a preparation experiment of nanoliposomes.

[0063] 4 parts of cycloastragenol, 2 parts of baicalein, 2 parts of quercetin and 20 parts of Tween 85 were mixed by mass ratio, and ultrasonically treated at 50°C for 50 minutes to obtain a mixture V-A;

[0064] 10 parts of castor oil, 8 parts of hydrogenated lecithin and 8 parts of anhydrous ethanol were mixed, and the mixture was stirred at 70°C and 450 rpm for 25 minutes to obtain a mixture V-B;

[0065] 30 parts of diethylene glycol monoethyl ether, 3 parts of poloxamer 407 and water were mixed, and the mixture was stirred at 250 rpm for 30 min at 50°C to obtain a mixture V-C.

[0066] The mixture V-B was cooled to 50°C and then slowly added into the mixture V-A, and stirred at 350 rpm for 20 min to obtain a mixture V-D;

[0067] The mixture V-C was added dropwise into the mixture V-D under shear conditions, with a shear rate of 8000 rpm, a temperature of 50°C and a time of 10 min; then the mixture was transferred to a high-pressure homogenizer and subjected to a high-pressure homogenization cycle treatment at a pressure of 100 MPa, cycled 5 times, and cooled to room temperature to obtain liposome V.

[0068] Comparative Example 3

[0069] This example provides a preparation experiment of nanoliposomes.

[0070] 4 parts of cycloastragenol, 2 parts of curcumin, 2 parts of quercetin and 20 parts of Tween 85 were mixed by mass ratio, and ultrasonically treated for 50 minutes at 50°C to obtain a mixture VI-A;

[0071] 10 parts of castor oil, 8 parts of hydrogenated lecithin and 8 parts of anhydrous ethanol were mixed, and the mixture was stirred at 70°C and 450 rpm for 25 minutes to obtain a mixture VI-B;

[0072] 30 parts of diethylene glycol monoethyl ether, 3 parts of poloxamer 407 and water were mixed, and the mixture was stirred at 250 rpm for 30 min at 50°C to obtain a mixture VI-C.

[0073] The mixture VI-B was cooled to 50°C and then slowly added into the mixture VI-A, and stirred at 350 rpm for 20 min to obtain a mixture VI-D;

[0074] The mixture VI-C was added dropwise into the mixture VI-D under shear conditions, with a shear rate of 8000 rpm, a temperature of 50°C and a time of 10 min; then the mixture was transferred to a high-pressure homogenizer and subjected to a high-pressure homogenization cycle treatment at a pressure of 100 MPa, cycled 5 times, and cooled to room temperature to obtain liposome VI.

[0075] Comparative Example 4

[0076] This example provides a preparation experiment of nanoliposomes.

[0077] 4 parts of cycloastragenol, 2 parts of curcumin, 2 parts of baicalin and 20 parts of Tween 85 were mixed by mass ratio, and ultrasonically treated at 50°C for 50 minutes to obtain a mixture VII-A;

[0078] 10 parts of castor oil, 8 parts of hydrogenated lecithin and 8 parts of anhydrous ethanol were mixed, and the mixture was stirred at 70°C and 450 rpm for 25 minutes to obtain a mixture VII-B;

[0079] 30 parts of diethylene glycol monoethyl ether, 3 parts of poloxamer 407 and water were mixed, and the mixture was stirred at 250 rpm for 30 min at 50°C to obtain a mixture VII-C.

[0080] The mixture VII-B was cooled to 50°C and then slowly added to the mixture VII-A, and stirred at 350 rpm for 20 min to obtain a mixture VII-D;

[0081] The mixture VII-C was added dropwise into the mixture VII-D under shear conditions, with a shear rate of 8000 rpm, a temperature of 50°C and a time of 10 min; then it was transferred to a high-pressure homogenizer and subjected to a high-pressure homogenization cycle treatment at a pressure of 100 MPa, cycled 5 times, and cooled to room temperature to obtain liposome VII.

[0082] Experimental Example 1

[0083] This experimental example provides a stability test experiment of nanoliposomes.

[0084] The object to be tested was placed in a sealed container at -18°C, 4°C, room temperature and 45°C for 180 days. The precipitation or discoloration was observed at the initial state, 90 days and 180 days later, and the particle size of the object to be tested was measured.

[0085] In this experimental example, the liposomes prepared in Examples 1 to 3 and Comparative Examples 1 to 4 were used as test objects, and the performance of each liposome was detected to obtain results. All Examples and Comparative Examples did not precipitate or discolor at all temperatures. The measured particle size results are shown in Table 1.

[0086] Table 1 Particle size results (nm)

[0087]

[0088] As shown in Table 1, the liposomes prepared in Examples 1 to 3 and Comparative Examples 1 to 4 all showed good stability, and no aggregation and stratification occurred after being placed at -18°C, 4°C, room temperature and 45°C for 180 days. It can be seen that the preparation method provided by the present invention is of great significance for promoting the stability of the product. The particle size and particle size variation of liposome I prepared in Example 1 are the smallest, and the system is the most stable.

[0089] Experimental Example 2

[0090] This experimental example provides a cell anti-inflammatory experiment of nanoliposomes.

[0091] RAW 264.7 cells in the logarithmic growth phase were inoculated in a 24-well plate at a cell density of (2-5)×10 5 / mL, 0.5mL per well, incubate for 24h. Aspirate the supernatant and add 0.5mL of the following samples respectively: ① Normal group: DMEM medium (+2% FBS + 1% double antibody); ② LPS group: 1μg / mL LPS; ③ Experimental group: test substance (diluted to 10%) + LPS (1μg / mL). After each group of cells were treated for 24h, the supernatant was aspirated into a centrifuge tube with a pipette, centrifuged at 1000r / min for 5min, the supernatant was aspirated, and the changes in the amount of inflammatory factors in the supernatant were detected using TNF-α and IL-6 inflammatory factor detection kits.

[0092] In this example, the liposomes prepared in Examples 1 to 3 and Comparative Examples 1 to 4 were used as the test objects in the experimental group to test the anti-inflammatory performance of each liposome. Figure 1 Results shown.

[0093] Depend on Figure 1 It can be seen that after LPS induction, the inflammatory factors TNF-α and IL-6 were expressed in large quantities in the LPS group cells, and the inflammation induction model was successfully established. Compared with the LPS group, the expression of inflammatory factors TNF-α and IL-6 in the cells of Examples 1 to 3 in the experimental group was significantly reduced, and the degree of reduction was stronger than that of Comparative Examples 1 to 4. It can be seen that the nanoliposomes provided by the present invention have an excellent effect of improving cell inflammation.

[0094] Experimental Example 3

[0095] This experimental example provides an anti-oxidative damage experiment of nanoliposomes.

[0096] The test substance was diluted with DMEM complete medium at a final concentration of 10% to obtain a test substance dilution solution; H2O2 was diluted to 800 μM with DMEM medium to obtain a H2O2 dilution solution. HaCaT cells (human immortalized keratinocytes) in the logarithmic growth phase were cultured at 8×10 3 The dose of 100 μL / well was inoculated in a 96-well plate, and each well was filled with 100 μL of PBS. The outermost circle of the 96-well plate was sealed with 100 μL of PBS. After 24 hours, the cells were completely attached to the wall and replaced with the diluent of the test substance. The cells were cultured for another 24 hours. The supernatant was discarded and H2O2 diluent was given and cultured in an incubator. A normal group without the diluent of the test substance and H2O2 diluent and an H2O2 group without the diluent of the test substance were set up. Immediately after 4 hours of culture, the cell activity was detected using the CCK8 method, and the detection wavelength was 450nm.

[0097] In this example, the liposomes prepared in Examples 1 to 3 and Comparative Examples 1 to 4 were used as test objects to test the antioxidant properties of each liposome. Figure 2 Results shown.

[0098] Depend on Figure 2It can be seen that the cell viability of the H2O2 group decreased significantly, indicating that the H2O2 injury model was successfully established. Compared with the H2O2 group, the liposomes prepared in Examples 1 to 3 significantly improved the viability of damaged cells (P < 0.0001), and the improvement effects were all better than the comparative examples, among which the improvement effect of Example 1 was the most significant. It can be seen that the nanoliposomes provided by the present invention have excellent effects on improving cell oxidative damage.

[0099] Experimental Example 4

[0100] This experimental example provides an antibacterial experiment of nanoliposomes.

[0101] The test substance was diluted with LB medium at a final concentration of 10% to obtain a test substance dilution solution. Staphylococcus aureus (Gram-positive bacteria, 1×10 6 cfu / mL): 10% saline + 90% LB medium (negative group), 5 μg / mL penicillin G sodium solution (positive group), test dilution (experimental group); Escherichia coli (Gram-negative bacteria, 1×10 6 cfu / mL): 10% saline + 90% LB medium (negative group), streptomycin sulfate solution 5μg / mL (positive group), test dilution (experimental group). After incubation at 37°C for 24h according to the above grouping, the generated colonies were counted, and the inhibition rate was calculated according to the formula inhibition rate (%) = (number of colonies in the experimental group / number of colonies in the negative group) × 100%. When the inhibition rate is ≥70, it is considered to have an antibacterial effect.

[0102] In this experimental example, the liposomes prepared in Examples 1 to 3 were used as test objects to test the antibacterial properties of each liposome. Figure 3 And the results shown in Table 2.

[0103] Table 2 Antibacterial test results

[0104]

[0105] Depend on Figure 3 As shown in Table 2, the liposome emulsions prepared in Examples 1 to 3 can significantly inhibit Staphylococcus aureus and Escherichia coli (P < 0.01), and the antibacterial effect is close to that of the positive group. This shows that the liposome emulsion provided by the present invention can exert a relatively obvious inhibitory effect on Gram-positive bacteria Staphylococcus aureus and Gram-negative bacteria Escherichia coli.

[0106] Experimental Example 5

[0107] This experimental example provides a cell proliferation efficacy experiment of nanoliposomes.

[0108] The test substance was diluted with DMEM complete medium at a final concentration of 10% to obtain a test substance dilution solution; HDF cells (human skin fibroblasts) in the logarithmic growth phase were cultured at 8×10 3 The dose of cells / well was inoculated into a 96-well plate, with each well containing 100 μL of the system. The outermost circle of the 96-well plate was sealed with 100 μL of PBS. After 24 hours, when the cells were completely attached to the wall, the dilution of the test substance was replaced, and a blank group containing only culture medium was set up. After continuing to culture the cells for 48 hours, the cell activity was detected by CCK-8 method at a detection wavelength of 450 nm.

[0109] In this example, the liposomes prepared in Examples 1 to 3 and Comparative Examples 1 to 4 were used as test objects to detect the cell proliferation efficacy of each liposome. Figure 4 and Figure 5 Results shown.

[0110] Fibroblasts can not only synthesize and secrete collagen, elastin, and matrix components glycosaminoglycans and glycoproteins, but also generate collagen fibers, reticular fibers, and elastic fibers, playing an important role in the anti-aging process. Figure 4 and Figure 5 The results show that the cell viability of the blank group is 99.26%, indicating that human skin fibroblasts grow normally. Compared with the blank group, the liposomes prepared in Examples 1 to 3 can significantly promote the proliferation of human skin fibroblasts (P < 0.0001), and the promotion effect is better than that of Comparative Examples 1 to 4, among which the cell proliferation effect of Example 1 is the best. The results show that the liposomes prepared by the present invention have a good improvement effect on cell aging.

[0111] Experimental Example 6

[0112] This experimental example provides an anti-aging experiment of nanoliposomes.

[0113] 6hpf zebrafish of the same developmental stage were selected and placed in a covered culture dish with standard dilution water. The test substance was added with a final concentration of 10% and β-galactosidase staining was performed 120 hours later. At the same time, a normal control group with standard dilution water and a model group with 300μmol / L hydrogen peroxide were set up. After incubation overnight, photos were taken and recorded.

[0114] In this example, the liposomes prepared in Examples 1 to 3 were used as test objects to detect the anti-aging effects of each liposome. Figure 6 Results shown.

[0115] Skin aging is the result of complex factors, such as accumulation of reactive oxygen species, loss of collagen and elastin, increased activity of β-galactosidase, DNA damage, inflammatory response, etc. In the anti-aging experiment, the inhibitory effect of the test sample on β-galactosidase is tested by staining with β-galactosidase. The lower the staining degree, the stronger the anti-aging effect of the test sample. Figure 6 It can be seen that the staining intensity of Examples 1 to 3 is significantly lower than that of the model group, and is close to that of the normal control group, which indicates that the liposomes prepared by the present invention have a good inhibitory effect on β-galactosidase.

[0116] Although the preferred embodiments of the present invention have been described, those skilled in the art may make additional changes and modifications to these embodiments once they have learned the basic creative concept. Therefore, the appended claims are intended to be interpreted as including the preferred embodiments and all changes and modifications that fall within the scope of the present invention.

[0117] Obviously, those skilled in the art can make various changes and modifications to the present invention without departing from the spirit and scope of the present invention. Thus, if these modifications and variations of the present invention fall within the scope of the claims of the present invention and their equivalents, the present invention is also intended to include these modifications and variations.

Claims

1. A nanoliposome with high antibacterial and β-galactosidase activity inhibition, characterized in that: Every 100 parts by weight comprises: 2-4 parts of cycloastragenol, 1-3 parts of curcumin, 1-3 parts of baicalein, 1-3 parts of quercetin, 10-20 parts of surfactant, 5-10 parts of lecithin, 20-30 parts of co-surfactant, 5-10 parts of liquid lipid, 1-5 parts of enhancer, 5-10 parts of anhydrous ethanol, and the balance is water.

2. The nanoliposome according to claim 1, characterized in that Every 100 parts by weight comprises: 4 parts of cycloastragenol, 2 parts of curcumin, 2 parts of baicalein, 2 parts of quercetin, 20 parts of surfactant, 8 parts of lecithin, 30 parts of co-surfactant, 8 parts of liquid lipid, 3 parts of enhancer, 8 parts of anhydrous ethanol, and the balance is water.

3. The nanoliposome according to claim 1, characterized in that The surfactant is one or a combination of Tween 85, Tween 80, Tween 20, Span 80, Span 60, polyglycerol monooleate, polyglycerol-10 oleate, polyoxyethylene castor oil, and propylene glycol fatty acid ester; And / or, the lecithin is one or a combination of hydrogenated lecithin, soybean lecithin, egg yolk lecithin and sunflower lecithin; And / or, the co-surfactant is one or a combination of diethylene glycol monoethyl ether, 1,3-propylene glycol, 1,2-butylene glycol, 1,2-pentanediol, 1,2-hexanediol, dipropylene glycol, octyldodecanol, maltitol and lactitol; And / or, the liquid lipid is one or a combination of castor oil, corn oil, soybean oil, olive oil, rapeseed oil, linoleic acid, camellia oil, medium chain triglycerides, caprylic and capric monoglycerides and diglycerides, sucrose fatty acid esters, and isopropyl myristate; And / or, the reinforcing agent is one or a combination of polypropylene oxide block copolymer, chitosan, polyethylene glycol, pectin, polyethylene oxide, polylactic acid-glycolic acid copolymer.

4. A method for preparing nanoliposomes according to any one of claims 1 to 3, characterized in that: The following steps are involved: The cycloastragenol, the curcumin, the baicalein, the quercetin and the surfactant are uniformly mixed to obtain a mixture A; Evenly mixing the liquid lipid, the lecithin and the anhydrous ethanol to obtain a mixture B; The co-surfactant, the enhancer and the water are uniformly mixed to obtain a mixture C; Adding the mixture B into the mixture A at 40-50° C. to obtain a mixture D; The mixture C is added dropwise into the mixture D under shearing conditions, and then subjected to high-pressure homogenization circulation treatment and cooled to room temperature to obtain the nanoliposomes.

5. The preparation method according to claim 4, characterized in that: The preparation conditions of the mixture A are as follows: ultrasonic treatment at 40-60° C. for 30-50 min; And / or, the preparation conditions of the mixture B are: stirring at 50-80° C. and 300-500 rpm for 15-30 min; And / or, the preparation conditions of the mixture C are: stirring at 40-60° C. and 100-300 rpm for 20-30 min; And / or, the preparation conditions of the mixture D are: stirring at a speed of 200 to 400 rpm for 10 to 20 min; And / or, the shearing conditions are: rotation speed 6000-8000 rpm, temperature 40-60° C., time 5-15 min; And / or, the number of cycles of the high-pressure homogenization cycle treatment is 4 to 6 times.

6. Use of the nanoliposome according to any one of claims 1 to 3 or the nanoliposome prepared by the preparation method according to any one of claims 4 to 5 in the preparation of an antibacterial agent.

7. The use according to claim 6, characterized in that: The nanoliposomes are used to inhibit Gram-positive bacteria and / or Gram-negative bacteria.

8. The use according to claim 7, characterized in that: The nanoliposome is used for inhibiting Staphylococcus aureus and / or Escherichia coli.

9. Use of the nanoliposome according to any one of claims 1 to 3 or the nanoliposome prepared by the preparation method according to any one of claims 4 to 5 in the preparation of an anti-aging agent.

10. The use according to claim 9, characterized in that: The nanoliposomes are used to improve cellular inflammation; And / or, the nanoliposomes are used to improve cell oxidative damage; And / or, the nanoliposome is used to promote the proliferation of human skin fibroblasts; and / or, the nanoliposome is used to inhibit the action of β-galactosidase.

Citation Information

Patent Citations

  • Flavonoid polyphenol drug self-emulsifying composition, preparation method thereof, pharmaceutical composition and application of pharmaceutical composition

    CN111789815A

  • Curcumin liposome as well as preparation method and application thereof

    CN117859899A